Menu

Swedish Ethics Review Board: Macchiarini Is Guilty

The group calls for the retraction of six publications by surgeon Paolo Macchiarini regarding the synthetic trachea transplantations that led to the death of at least three patients. 

Oct 30, 2017
Jef Akst

YOUTUBE, ANNEWSThe Expert Group on Scientific Misconduct at Sweden’s Central Ethics Review Board (CEPN) has found evidence of scientific misconduct in all six of Paolo Macchiarini’s synthetic trachea transplantation publications it reviewed. The papers reported on the implantations of three patients with artificial tracheae—all of whom died.

“[T]he transplantations are described successfully in the articles, which is not the fact,” the Expert Group on Scientific Misconduct said in a statement last week (October 27). “The Expert Group also establish[ed] that the information in the articles are misleading and beautifying regarding the patients conditions and furthermore that information has been withhold in this purpose and that this constitutes scientific misconduct. In addition, there is false information of ethical approval, which also constitute[s] scientific misconduct.” The group—composed of University of Uppsala professor of surgery Martin Björck and Detlev Ganten, a professor emeritus of pharmacology and former CEO of the Charité—recommends the retraction of all six articles.

The report, released on October 20, further concluded that it was not just Macchiarini who was at fault, but that all coauthors on the six articles in question are also guilty of misconduct. “The responsibility is however different amongst the authors,” according to the statement. “The main responsibility lies on Paolo Macchiarini as the main author and research-leader and others who have had a more prominent role in the research and the authorship. The more detailed responsibility and the future consequences for the respective authors is up to their employers to decide.”

Macchiarini was first found guilty of misconduct in May 2015 following accusations of improper ethical review for the transplant procedures, when an independent investigator commissioned by Macchiarini’s employer, the Karolinska Institute, reviewed the surgeon’s papers and found that the data did not jibe with hospital records. But that finding was rejected by the institute, which cleared Macchiarini of wrongdoing. It wasn’t until the following February that Karolinska administrators decided to reexamine Macchiarini’s case, after a Swedish documentary series aired new details on his work. A month later, the institute terminated his contract, and in December 2016, formally announced that he had been found guilty of misconduct.

In addition to these misconduct investigations, Swedish prosecutors considered pursuing manslaughter charges against Macchiarini, but these were dropped earlier this month. In the new report, the Expert Group “makes no pronouncement on whether their deaths are a consequence of the synthetic trachea implants. However, the material as a whole shows that in no case did the transplant attain functional status, but on the contrary gave rise to serious complications.”

“No patient should be subjected to experiments in Swedish care. Little consolation for those who got hurt,” Helene Hellmark Knutsson, Sweden’s higher education and research minister, tweeted today (translation courtesy of The Local).

(Hat tip to Leonid Schneider)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.